Home | Harrow, Inc.
Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.
About | Harrow, Inc.
Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance …
Harrow Launches VEVYE® Access for All
Mar 17, 2025 · Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical …
Careers | Harrow, Inc.
At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together. Humility, ownership, preparedness, and entrepreneurship create the foundation for a culture where …
SEC Filings | Harrow, Inc.
Nov 18, 2025 · The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
In June 2025, Harrow acquired the exclusive U.S. commercial rights for BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% for the treatment of post-operative inflammation and pain …
0001493152-25-012840 | 8-K | iXBRL Viewer | Harrow INC
Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).
Leadership | Harrow, Inc.
Prior to joining Harrow, he was Founder and Chief Executive Officer of LVMA Consulting, advising emerging biotech companies and top 10 global pharmaceutical organizations on commercial …
News - Harrow, Inc.
Sep 15, 2025 · November 24, 2025 Harrow to Present at Two Investor Conferences in December November 18, 2025 Harrow Announces Closing of Acquisition of Melt Pharmaceuticals November …
Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information …